

Handbook of
Neurochemistry

SECOND EDITION

Volume 6

**RECEPTORS IN
THE NERVOUS SYSTEM**

Edited by

Abel Lajtha

Handbook of
Neurochemistry

SECOND EDITION

Volume 6
***RECEPTORS IN
THE NERVOUS SYSTEM***

Edited by
Abel Lajtha

*Center for Neurochemistry
Wards Island, New York*

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Main entry under title:

Handbook of neurochemistry.

Includes bibliographical references and index.

Contents: v. 1. Chemical and cellular architecture—v. 2. Experimental neurochemistry—[etc.]—v. 6. Receptors in the nervous system.

1. Neurochemistry—Handbooks, manuals, etc. 2. Neurochemistry. I. Lajtha, Abel, [DNLM: 1. Neurochemistry. WL 104 H235 1982]

QP356.3.H36 1982

612'.814

82-493

ISBN 0-306-41411-2 (v. 6)

©1984 Plenum Press, New York

A Division of Plenum Publishing Corporation

233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Handbook of
Neurochemistry

SECOND EDITION

Volume 6

**RECEPTORS IN
THE NERVOUS SYSTEM**

Handbook of Neurochemistry

SECOND EDITION

Edited by Abel Lajtha

Center for Neurochemistry, Wards Island, New York

Volume 1 • CHEMICAL AND CELLULAR ARCHITECTURE

Volume 2 • EXPERIMENTAL NEUROCHEMISTRY

Volume 3 • METABOLISM IN THE NERVOUS SYSTEM

Volume 4 • ENZYMES IN THE NERVOUS SYSTEM

Volume 5 • METABOLIC TURNOVER IN THE NERVOUS SYSTEM

Volume 6 • RECEPTORS IN THE NERVOUS SYSTEM

Volume 7 • STRUCTURAL ELEMENTS OF THE NERVOUS SYSTEM

Volume 8 • NEUROCHEMICAL SYSTEMS

*Volume 9 • ALTERATIONS OF METABOLITES IN THE NERVOUS
SYSTEM*

Volume 10 • PATHOLOGICAL NEUROCHEMISTRY

Contributors

R. D. Allan, Department of Pharmacology, University of Sydney, Sydney NSW 2006 Australia

Kenneth A. Bonnet, Department of Psychiatry, Millhauser Laboratories, New York University School of Medicine, New York, New York 10016

Anna Borsodi, Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, H-6701 Szeged, Hungary

S. Bourgoin, Groupe NB, INSERM U. 114, Collège de France, 75231 Paris, Cedex 05, France

David R. Burt, Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201

De-Maw Chuang, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, DC 20032

M. Blair Clark, Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129

E. Costa, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, DC 20032

Frederick J. Elhert, Departments of Pharmacology, Internal Medicine, Biochemistry, Psychiatry, and the Arizona Research Laboratories, University of Arizona Health Sciences Center, Tucson, Arizona 85724

Yigal H. Ehrlich, Neuroscience Research Unit, Departments of Psychiatry and Biochemistry, University of Vermont College of Medicine, Burlington, Vermont 05405

S. J. Enna, Departments of Pharmacology, Neurobiology and Anatomy, University of Texas Medical School at Houston, Houston, Texas 77025

Marianne Fillenz, University Laboratory of Physiology, Oxford, Oxford OX1 3PT England

- Arnold J. Friedhoff*, Department of Psychiatry, Millhauser Laboratories, New York University School of Medicine, New York, New York 10016
- Kelvin W. Gee*, Departments of Pharmacology, Internal Medicine, Biochemistry, Psychiatry, and the Arizona Research Laboratories, University of Arizona Health Sciences Center, Tucson, Arizona 85724
- C. Goetz*, Groupe NB, INSERM U. 114, Collège de France, 75231 Paris, Cedex 05, France
- Jack Peter Green*, Department of Pharmacology, The Mount Sinai School of Medicine of the City University of New York, New York, New York 10029
- Louise H. Greenberg*, Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129
- M. Hamon*, Groupe NB, INSERM U. 114, Collège de France, 75231 Paris, Cedex 05, France
- Edith D. Hendley*, Department of Physiology and Biophysics, University of Vermont College of Medicine, Burlington, Vermont 05405
- Fusao Hirata*, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, Maryland 20205
- Lindsay B. Hough*, Department of Pharmacology, The Mount Sinai School of Medicine of the City University of New York, New York, New York 10029
- G. A. R. Johnston*, Department of Pharmacology, University of Sydney, Sydney NSW, 2006 Australia
- Giulio Levi*, Istituto di Biologia Cellulare, Consiglio Nazionale delle Ricerche, 00196 Rome, Italy
- Bertha K. Madras*, Psychopharmacology Section, Clarke Institute of Psychiatry, Toronto, Ontario M5T 1R8 Canada
- Mario Marchi*, Istituto di Farmacologia e Farmacognosia, Università di Genova, 16146 Genoa, Italy
- Guido Maura*, Istituto di Farmacologia e Farmacognosia, Università di Genova, 16146 Genoa, Italy
- Edith McGeer*, Kinsmen Laboratory of Neurological Research, Department of Psychiatry, The University of British Columbia, Vancouver, British Columbia V6T 2A1 Canada

Patrick L. McGeer, Kinsmen Laboratory of Neurological Research, Department of Psychiatry, The University of British Columbia, Vancouver, British Columbia V6T 2A1 Canada

S. El Mestikawy, Groupe NB, INSERM U. 114, Collège de France, 75231 Paris, Cedex 05, France

Neville N. Osborne, Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford OX2 6AW England

Maurizio Raiteri, Istituto di Farmacologia e Farmacognosia, Università di Genova, 16146 Genova, Italy

William R. Roeske, Departments of Pharmacology, Internal Medicine, Biochemistry, Psychiatry, and the Arizona Research Laboratories, University of Arizona Health Sciences Center, Tucson, Arizona 85724

Jack W. Schweitzer, Department of Psychiatry, Millhauser Laboratories, New York University School of Medicine, New York, New York 10016

Najam R. Sharif, Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201.
Present Address: Department of Biochemistry, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom

Eric J. Simon, Departments of Psychiatry and Pharmacology, New York University School of Medicine, New York, New York 10016

J. H. Skerritt, Department of Pharmacology, University of Sydney, Sydney NSW 2006 Australia

Richard F. Squires, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962

Benjamin Weiss, Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129

Michael Williams, Nova Pharmaceutical Corporation, Baltimore, Maryland 21228

Maria Wollemann, Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, H-6701 Szeged, Hungary

Henry I. Yamamura, Departments of Pharmacology, Internal Medicine, Biochemistry, Psychiatry, and the Arizona Research Laboratories, University of Arizona Health Sciences Center, Tucson, Arizona 85724

Foreword

A major advance in the biological sciences in the past decade has been the biochemical identification of cell membrane receptors. The existence of receptor substances on the surface of cells that recognize and bind to extracellular molecules was proposed at the beginning of the century by the pharmacologist and immunologist Paul Ehrlich and the physiologist J. N. Langley. Since then, receptors have been found to play an important role in numerous physiological and pathological processes. Over the years many attempts have been made to physically isolate and chemically characterize receptors, but because of the receptors' extremely low concentration and membrane localization, these efforts have met with limited success. Yet, despite the failure to characterize receptor substances, the concept of the presence of such molecules has had considerable heuristic value. Using pharmacological, physiological, and immunologic approaches, researchers have identified several specific receptors, e.g., α - and β -adrenergic, nicotinic and muscarinic cholinergic, and histaminergic. With the characterization of various types of receptors on cell membranes, many drugs were developed that proved to be experimentally and therapeutically useful.

It was only in the early 1970s that methods for the specific measurement, chemical characterization, and physical isolation of cell membrane receptors were developed. These advances were made possible by the availability of ligands with high specific radioactivity that retained their biological activity and of experimental procedures that differentiated between specific and non-specific binding of ligands. Another reason for the rapid advances in receptor research was the recognition that experimental data had to fulfill certain criteria, including the following: (1) structural and steric binding properties of agonists and antagonists should be consistent with their biological activity; (2) ligand binding to the receptor should show high affinity and saturability at concentrations that elicit a biological response; and (3) the specific binding should be greatest in tissues responsive to selective agonists.

Once suitable radioactive ligands were available, and rigorous criteria for the characterization of interaction of ligands with their receptors were established, many previously unrecognized receptors were found. Among the more significant were opiate, neuropeptide, and benzodiazepine receptors. Many of these discoveries were especially important to neurochemistry and opened a new dimension in this field.

This volume presents examples of the richness and variety of receptor research that is especially relevant to neurochemistry. In spite of the many advances concerning receptors, what we know is just the tip of the iceberg. We are just beginning to understand how receptors transduce their specific information through membranes. Receptors are in a dynamic state, continuously changing the cell's responsiveness to its environment. There is much to be learned about how these changes come about. With the development of powerful new technologies and instrumentation, the next decade in receptor research promises to be even more exciting than the past one.

Julius Axelrod

Contents

Chapter 1

Mammalian Central Adenosine Receptors

Michael Williams

1. Introduction	1
2. Adenosine Effects in the Mammalian Central Nervous System ...	2
2.1. Cyclic Nucleotide Metabolism	2
2.2. Electrophysiological Studies	3
2.3. Effect of Adenosine on Neurotransmitter Release	5
2.4. Behavioral Effects of Adenine Nucleosides and Nucleotides	7
2.5. Endogenous Adenosine in the Mammalian Central Nervous System	8
3. Adenosine Receptors	11
4. Radioligand Binding to Central Adenosine Receptors	12
5. Autoradiographic Localization of Adenosine Radioligand Binding	17
6. Alterations in Adenosine Radioligand Binding	18
7. Possible Physiological Roles of Adenosine in the Central Nervous System	18
7.1. Adenosine and Anxiolytics	18
7.2. Adenosine and Antidepressants	19
7.3. Adenosine and Analgesics	20
8. Conclusions	20
References	21

Chapter 2

α -Adrenergic Receptors

Arna Borsodi and Maria Wollemaun

1. Introduction	27
2. Binding of Radioactive Ligands to α -Adrenergic Receptors	28

2.1. Binding of Agonists	28
2.2. Binding of Antagonists	29
3. Heterogeneity of α -Adrenergic Receptors	29
3.1. Subtypes of α -Adrenergic Receptors	29
3.2. Heterogeneity in Subtypes of α -Adrenergic Receptors	31
4. Inhibition of Adenylate Cyclase through α -Adrenergic Receptors	31
5. Solubilization and Purification of α -Adrenergic Receptors	32
6. Regulation of α -Adrenergic Receptors	32
6.1. Regulation by Guanine Nucleotides	32
6.2. Regulation by Cations	33
6.3. Physiological Regulation	33
7. Mechanism of α -Adrenergic Action	34
8. Conclusions	34
References	35

Chapter 3

β -Adrenergic Receptors

Maria Wollemann and Anna Borsodi

1. Introduction	39
2. β -Adrenergic Receptor	40
2.1. β -Adrenergic Receptor Binding Sites	40
2.2. Activation and Inhibition of Adenylate Cyclase through β -Adrenergic Receptors	41
2.3. Solubilization and Purification of β -Adrenergic Receptor and Adenylate Cyclase	42
2.4. Attempts at Reconstitution of the β -Adrenergic Receptor Activation of Adenylate Cyclase	44
3. Regulation of the β -Adrenergic Receptor	45
3.1. Supersensitivity of β -Adrenergic Receptor and Adenylate Cyclase Activation	45
3.2. Desensitization of β -Adrenergic Receptor and Adenylate Cyclase Activation	45
3.3. Pathological Changes of β -Adrenergic Receptors	46
4. Conclusions	47
References	48

Chapter 4

Norepinephrine

Marianne Fillenz

1. Introduction	51
2. Storage of Norepinephrine	52

2.1. Large Dense-Cored Vesicles	52
2.2. Small Dense-Cored Vesicles	54
2.3. Dopamine- β -Hydroxylase in the Neuron	57
2.4. Summary	59
3. Norepinephrine Release	59
3.1. Release by Exocytosis	59
3.2. Carrier-Mediated Release	61
3.3. Regulation of Release	61
3.4. Summary	62
4. Norepinephrine Synthesis	62
4.1. Rapid Regulation	62
4.2. Slow Regulation	63
4.3. Functional Implications	64
5. Conclusion	65
References	66

Chapter 5

Dopamine

Bertha Kalifon Madras

1. Introduction	71
2. Dopamine	72
2.1. Dopamine Distribution	72
2.2. Synthesis and Storage	74
2.3. Release, Uptake, and Metabolism	74
3. Dopamine Function	75
3.1. Psychiatric, Neurological, and Endocrinological Function	75
3.2. Dopaminergic Behavior in Animals	77
3.3. Neurophysiological Activity	78
4. Dopamine Receptor Identification <i>in Vitro</i>	78
4.1. Terminology	78
4.2. Tritiated Ligands for Receptors	79
4.3. Criteria for Receptor Identification	79
4.4. Properties of Dopamine Receptors	81
4.5. Correlation of Binding Data with Pharmacological, Clinical, and Behavioral Data	90
5. Dopamine Receptor Distribution	90
5.1. Occurrence in Different Species	90
5.2. Brain Regional Distribution	90
5.3. Cellular and Subcellular Distribution	92
5.4. Peripheral Tissue Distribution	92
6. Dopamine Receptor Regulation	93
6.1. Schizophrenia	93

6 2. Tardive Dyskinesia and Parkinson's Disease	94
6 3. Neuroleptic-Induced Receptor Adaptation	94
6 4. Dopamine Agonist-Induced Receptor Adaptation	95
6 5. Hormone Regulation	95
7. Clinical Applications of Dopamine Receptors	96
7.1. Assay of Neuroleptic Concentrations in Blood	96
7.2. Lymphocyte Dopamine Receptors?	97
8. Dopamine Receptor Purification	97
8.1. Solubilization of Dopamine Receptors	97
8.2. Purification	98
9. Future Directions	98
References	99

Chapter 6

Central Serotonin Receptors

M. Hamon, S. Bourgoin, S. El Mestikawy and C. Goetz

1. Current Vistas on Serotonin in the Central Nervous System	107
1.1 Anatomic Distribution of 5-HT	107
1.2. Serotonin Synthesis	108
1.3. Serotonin Inactivation	110
2. Characteristics of 5-HT Receptors in the Central Nervous System	111
2.1. Pharmacological Observations	111
2.2. Biochemical Studies	112
2.3. Characteristics of Specific Binding Sites for 5-HT	114
2.4. Characteristics of 5-HT-Sensitive Adenylate Cyclase in the CNS	119
2.5. Physicochemical Properties of Central 5-HT Receptors	119
2.6. <i>In vitro</i> Modulations of 5-HT Receptors	121
2.7. <i>In vivo</i> Modulations of 5-HT Binding Sites	127
2.8. <i>In vivo</i> Modulations of 5-HT-Sensitive Adenylate Cyclase	134
2.9. Functional Correlates of 5-HT Receptors	135
3. Conclusion and Future Trends	138
References	139

Chapter 7

Histamine and Its Receptors in the Nervous System

Lindsay B. Hough and Jack Peter Green

1. Introduction	145
2. Measurement of Histamine in Neural Issues	145

3. Formation of Histamine	148
4. Storage and Fate of Histamine	149
4.1. Storage	149
4.2. Release	151
4.3. Uptake	151
4.4. Catabolism	152
4.5. Turnover	157
4.6. Pharmacological Activity of Histamine Catabolites	158
5. Localization of Histamine	159
5.1. Regional Localization	159
5.2. Cellular Localization	160
6. Ontogeny of Histamine in Brain	166
7. Histamine in the Invertebrate Nervous System	168
8. Histamine in the Peripheral Nervous System	169
9. Considerations in the Use of Agonists and Antagonists to Classify Histamine Receptors and to Impute Functions to Histamine	170
10. Histamine Receptors	173
10.1. The Histamine H ₁ Receptor	173
10.2. The Histamine H ₂ Receptor	179
10.3. Electrophysiological Effects Associated with Histamine Receptors	184
11. Functions of Histamine in Brain	186
11.1. Functions that May Be Associated with Mast Cells	186
11.2. Behavior	187
11.3. Central Sympathetic Activity	190
11.4. Temperature Regulation	190
11.5. Hormone Release	190
12. Effects of Psychotropic Drugs on Brain Histamine and Its Receptors	191
12.1. Opiates	191
12.2. Antidepressant Drugs	192
12.3. Neuroleptic Drugs	194
12.4. Hallucinogens	195
12.5. Significance of the Interaction of Psychotropic Drugs with Histamine Receptors	196
13. Summary	197
References	200

Chapter 8

GABA Receptors

G. A. R. Johnston, R. D. Allan, and J. H. Skerritt

1. Introduction	213
2. GABA Analogues	214
3. Electrophysiological Studies	215

3.1. GABA Antagonists	215
3.2. GABA Agonists	217
3.3. GABA Modulators	221
4. Behavioral Studies	222
5. Binding Studies	223
5.1. Ligands	224
5.2. Detergents, Inorganic Ions, and Multiple Binding Sites	225
6. Endogenous Inhibitors (GABARINS)	227
6.1. Occluded GABA	228
6.2. Phospholipids	228
6.3. Peptides	229
6.4. Other Endogenous Inhibitors	230
7. Developmental and Phylogenetic Trends	230
8. Drug Effects on GABA Binding	231
8.1. Enhancement of GABA Binding by Barbiturates	231
8.2. Enhancement of GABA Binding by Benzodiazepines	232
9. Conclusions	233
References	233

Chapter 9

Excitatory Amino Acid Receptors

Najam A. Sharif

1. Introduction	239
2. Receptor-Labeling Studies	240
2.1. Binding Methodology and Interpretation	240
2.2. Optimization of Conditions for Excitatory Amino Acid Binding	240
3. Cerebral Glutamate Receptors	241
3.1. Binding Characteristics	241
3.2. Pharmacology of [³ H]Glutamate Binding	244
3.3. Regulation of Glutamate Receptors	246
3.4. Chemical Modification Studies	248
4. Kainate Binding	249
5. L-Aspartate Receptors	250
6. Cysteine Sulfinate Binding	251
7. Additional Topics	252
7.1. Ontogeny and Localization of Receptors	252
7.2. Neuropathology of Excitatory Amino Acids	253
7.3. Stability of Receptor Sites	253
8. Concluding Remarks	254
References	256

Chapter 10

*Benzodiazepine Receptors**Richard F. Squires*

1. Introduction	261
2. General Properties of Benzodiazepine Receptors	262
3. Localization of Benzodiazepine Receptors in the Central Nervous System	263
4. "Peripheral" or "Kidney-Type" Benzodiazepine Receptors	265
5. Association of GABA Receptors with Benzodiazepine Receptors	266
6. Association of Anion Recognition Sites with Benzodiazepine Receptors	269
7. Association of Cation Recognition Sites with Benzodiazepine Receptors	271
8. Association of Picrotoxin-Barbiturate Sites with Benzodiazepine Receptors	275
9. Benzodiazepine Receptor Multiplicity	278
10. Solubilized Benzodiazepine Receptors	282
11. Photolabeling of Benzodiazepine Receptors	284
12. The Elusive "Endogenous Ligand"	286
13. The β -Carboline Story	289
14. Other Novel Substances that Interact with Benzodiazepine Receptor Complexes	293
15. Tentative Conclusions	298
References	299

Chapter 11

*Recognition Sites for Antidepressant Drugs**De-Maw Chuang and E. Costa*

1. Introduction	307
2. Presynaptic Adaptive Changes following Repeated Injections of Antidepressant Drugs	308
2.1. Changes in Monoamines	308
2.2. Effects of Antidepressants on α_2 -Adrenergic Receptors	310
3. Postsynaptic Adaptive Changes following Repeated Daily Injections of Antidepressants	310
3.1. β -Adrenergic Receptors	310
3.2. α -Adrenergic Receptors	313
3.3. Serotonergic Receptors	313
4. Are Neurotransmitter Recognition Sites Associated with the Recognition Sites for Antidepressant Drugs?	315
4.1. Adrenergic	315